Skip to content
Should Everybody Be On A GLP-1? episode artwork

Nov 3, 2024 12 min

Should Everybody Be On A GLP-1?

from Signet Hosted by David S. Filippi, MD

Semaglutide and tirzepatide have reshaped diabetes and weight-loss treatment, but could these drugs hold even greater potential? Join Dr. David S. Filippi—and his AI friends—on a quick journey into emerging data, revealing mechanisms, benefits, and mysteries of these breakthrough medications. Are they the most significant drugs of our time? Listen in and decide. Visit us at significant-podcast.com. Note: Signet is a brief, AI-generated summary of the Significant Podcast and may contain amusing or unexpected errors.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Should Everybody Be On A GLP-1?

0:00 12:46

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Frequently asked questions

How long is this episode of Signet?

This episode is 12 minutes long.

When was this Signet episode published?

This episode was published on November 3, 2024.

Can I download this Signet episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.